Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARVIVA: BCD-264 vs Darzalex in RRMM
NCT06296121Phase 3Recruiting
- Sponsor
- BIOCAD
- Start
- Dec 2023
- Primary completion
- Jan 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bcd-264 in multiple myeloma (MM) (2 arms), sponsored by BIOCAD. Primary endpoint: Overall Response Rate at 24 weeks. Started Dec 2023; status: recruiting.
02
Drugs
bcd-264
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06296121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06296121.